As the ink dries on the US approval of Novartis' heart failure treatment Entresto, talk has quickly shifted to pricing issues, and possible outcomes-based plans, rather than the drug's very ...

Even as Novartis takes home a partial win in court tied to its key blockbuster Entresto, the Swiss drugmaker continues to ...

" data-display-label="0" data-show-count="1" data-bookmark-label="Save" data-bookmarked-label="Saved" data-loggedin="0" ...

Novartis was expecting a lot from its PARAGON-HF trial of Entresto in heart failure with preserved ejection fraction (HFpEF) and isn’t letting a missed endpoint scupper the programme.

Swiss pharma major Novartis (NOVN: VX) is set to lay off 427 employees at its East Hanover, New Jersey, site as part of a ...

Developers of cardiology drugs and devices will be back in the spotlight this weekend when the annual scientific meeting of ...

A new analysis presented at the ACC 2025 meeting also finds that the new prices for heart failure drugs negotiated through Medicare will reduce hospitalizations. More Medicare Part D patients will ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

Both parties write to district court hours after Court of Appeals denies rehearing | MSN maintains that the Entresto patent ...

sent a federal judge competing letters clashing over whether the district court must wait for MSN’s push to get a key patent for Novartis’ Entresto delisted from the FDA’s approved-drugs ... MSN from ...

Both Verquvo and Entresto are oral tablets taken to prevent complications of heart failure. Verquvo is taken once daily, and Entresto is taken twice daily. Entresto is also available in capsule ...